The drug maker behind experimental obesity treatment retatrutide has stepped up its attack on a growing black market for the unapproved peptide, as Australian authorities warn of serious toxicity linked to products being sold online.
The drug maker behind experimental obesity treatment retatrutide has stepped up its attack on a growing black market for the unapproved peptide, as Australian authorities warn of serious toxicity linked to products being sold online.
This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.